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Abstract
Exercise phenotypes have played a key role for ensuring survival over human evolution. We speculated that some genetic
variants that influence exercise phenotypes could be associated with exceptional survival (i.e. reaching $100years of age).
Owing to its effects on muscle structure/function, a potential candidate is the Arg(R)577Ter(X) polymorphism (rs1815739) in
ACTN3, the structural gene encoding the skeletal muscle protein a-actinin-3. We compared the ACTN3 R577X genotype/
allele frequencies between the following groups of ethnically-matched (Spanish) individuals: centenarians (cases, n=64; 57
female; age range: 100–108 years), young healthy controls (n=283, 67 females, 216 males; 2162 years), and humans who
are at the two end-points of exercise capacity phenotypes, i.e. muscle endurance (50 male professional road cyclists) and
muscle power (63 male jumpers/sprinters). Although there were no differences in genotype/allele frequencies between
centenarians (RR:28.8%; RX:47.5%; XX:23.7%), and controls (RR:31.8%; RX:49.8%; XX:18.4%) or endurance athletes (RR:28.0%;
RX:46%; XX:26.0%), we observed a significantly higher frequency of the X allele (P=0.019) and XX genotype (P=0.011) in
centenarians compared with power athletes (RR:47.6%; RX:36.5%;XX:15.9%). Notably, the frequency of the null XX (a-actinin-
3 deficient) genotype in centenarians was the highest ever reported in non-athletic Caucasian populations. In conclusion,
despite there were no significant differences with the younger, control population, overall the ACTN3 genotype of
centenarians resembles that of world-class elite endurance athletes and differs from that of elite power athletes. Our
preliminary data would suggest a certain ‘survival’ advantage brought about by a-actinin-3 deficiency and the ‘endurance’/
oxidative muscle phenotype that is commonly associated with this condition.
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Introduction
Identifying candidate gene variants associated with ‘longevity
assurance’ is possible by studying the genotype of centenarians [1].
This group of people are the survival tail of population; indeed,
they escaped diseases of the pre-antibiotic era, and have
postponed/avoided several ageing-related diseases as well as their
fatal consequences [2]. Genetically we are still citizens of the
Paleolithic era living in the 21st century [3,4]. In the Paleolitithic
societies survival was essentially linked to exercise (e.g. ‘long time
tracking persistence’ for successful hunting) [5,6]. Therefore, it
would be plausible to speculate that some identified genetic
variants associated with exercise phenotypes could also be
associated with exceptional survival.
The ACTN3 gene encodes for the synthesis of a-actinin-3 in
skeletal-muscle fibres, a sarcomeric protein necessary for producing
‘explosive’ powerful contractions. A premature stop codon polymor-
phism [Arg(R)577Ter(X), rs1815739] in ACTN3 was first described
by North et al. [7]. This genetic variation, which probably preceded
the appearance of anatomically modern humans in Europe and Asia
(,40.000–60.000 years ago) can affect exercise phenotypes [8]. The
a-actinin-3 deficient XX genotype (with a frequency of ,18%
among European Caucasians) is believed to preclude top-level
athletic performance in ‘pure’ power and sprint sports (e.g. sprinting,
jumping events), especially in women [9]. In contrast, compared with
the general population, the X allele tends to be overrepresented in
those humans with an ‘extreme endurance phenotype’, i.e. elite
endurance athletes [9,10]. Mechanistic explanation for the latter
finding might be found in the a-actinin-3 knockout (KO) mouse
developed by Prof. North’s group. Compared with wild-type mice,
the muscles of the KO mouse exhibit 33% higher endurance and a
shift towards increased activity of mitochondrial oxidative metabo-
lism [8,11]. With regards to this, improved oxidative pathways in
mitochondria may be a common factor linking physical fitness and
decreased disease risk [12,13]. For the abovementioned reasons, it
could be speculated that the shift towards more efficient aerobic
metabolismassociated with the XXgenotype might confer a ‘survival
advantage’.
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allelic and genotypic frequency of the ACTN3 R577X polymor-
phism between Spanish centenarians (aged 100–108 years), and a
group of healthy young adults (controls, aged ,40 years) of the
same ethnic origin. A secondary aim was to compare the data
obtained in centenarians with those of two groups of humans who
show the two ‘extreme’ phenotypes of the exercise performance
continuum, i.e. elite (world-class) athletes excelling in endurance
and power sports respectively. We hypothesized that: (i) the XX
genotype tends to be overrepresented in centenarians compared
with the general population; (ii) the ACTN3 R577X allelic/
genotypic frequency distribution of centenarians is similar to that
of endurance athletes; and (iii) the XX genotype will be
overrepresented in centenarians compared with the power athlete
group.
Methods
The study was designed and carried out in accordance with the
recommendations for the human genotype-phenotype association
studies recently published by the NCI-NHGRI Working Group on
Replication in Association Studies [14]. These recommendations
include among others, the following items: indicating time period
and location of subject recruitment, success rate for DNA
acquisition, sample tracking methods, and genotyping with a
second technology in a second laboratory.
Participants
Written consent was obtained from each participant. The study
protocol was approved by the institutional ethics committee
(Universidad Europea de Madrid (UEM). Spain) and was in accordance
with the Declaration of Helsinki for Human Research of 1974 (last
modified in 2000).
All the study participants were of the same Caucasian (Spanish)
descent for $3 generations. The majority (,90%) of them lived
most of their lives and were born in the same areas of Spain (Meseta
Castellana, ,600 m altitude).
Young adults (controls)
Inclusion criteria for this group were (i) to be woman or a man,
aged #40 years, (ii) free of any diagnosed cardiometabolic disease,
(iii) having no known family history of high longevity (90+ years).
During year 2008, we extracted genomic DNA from saliva
samples of 283 University students of both genders (67 females,
216 males; mean6SD age: 2162 years) who met the aforemen-
tioned criteria and were randomly selected from two Universities
of the same city (Madrid, Spain): Universidad Polite ´cnica (N=200)
and UEM (n=83). Their maximal oxygen uptake (VO2max) was
48.064.3 ml?kg
21?min
21. These controls served as subjects in
previous research from our group [15,16].
Centenarians (cases)
During 2009–2010 we obtained DNA from saliva samples in 64
centenarians of both genders (57 female, 7 male; 10261 years,
range: 100, 108) living in nursing residencies of the Spain central
area (Meseta Castellana). The most prevalent diseases in the
centenarians’ cohort were osteoarthritis (72%), hypertension
(62.5%), dementia (50%) and coronary artery disease (30%).
Three centenarians were free of any diagnosed disease.
Elite endurance athletes
This sample included the best 50 professional male Spanish
(2663 years) road cyclists in the last years, i.e. all Tour de France
finishers one or more time, including stage winners and top-3
finishers [10]. Their VO2max was 73.166.2 ml?kg
21?min
21.
Elite power athletes
This sample included 63 elite power (track and field) Spanish
male athletes (2763 years), including the best Spanish jumpers
(n=18) and sprinters in recent years (n=45). Thirteen of them
were Olympians during the period 2000–2008. Their VO2max was
60.365.5 ml?kg
21?min
21.
Genotype assessment of the ACTN3 R577X
polymorphism
Genotyping was performed specifically for research purposes.
The researchers in charge of genotyping were totally blinded to
the participants’ identities, i.e. saliva samples were tracked solely
with bar-coding and personal identities were only made available
to the main study researcher who was not involved in actual
genotyping.
‘Reference’ genotyping
Genotyping was originally performed during 2008–2010 in the
genetics laboratory of UEM (Madrid) following previously
described methodology [10]. The polymerase chain reaction
(PCR) was performed in order to amplify the sequence containing
the mutation. A fragment of 291 bp was amplified with the
following primers: ACTN3-F 59- CTGTTGCCTGTGGTA-
AGTGGG labelled a 59 with VIC and ACTN3-R 59- TGGTCA-
CAGTATGCAGGAGGG. The PCR conditions were as follows:
initial denaturing at 95uC 5 min; 35 cycles at 95uC3 0s ,6 0 uC
30 s, 72uC 30 s and a final extension at 72uC 10 min. ACTN3
genotypes were established by enzymatic digestion of amplicons
with Dde I. The R577X change creates a restriction site resulting in
fragments of 108, 97 and 86 bp. Digestion of the R577 allele
results in fragments of 205 and 86 bp, and digestion of the 577X
allele results in fragments of 108, 97 and 86 bp. The digestion
products detected by capillary electrophoresis (ABI Prism 310
genetic analyzer; Applied Biosystems, Foster City, CA) were those
labelled with VIC, i.e. 108 bp for 577X, and 205 bp for R577.
Reliability assessment of genotype analysis in a second
laboratory
Following recent recommendations [14], genotype results of the
ACTN3 R577X polymorphism were replicated in a different
laboratory (Progenika Biopharma, Parque Tecnolo ´gico de Zamudio, Derio-
Vizcaya, Spain) using a different technology, i.e. newly developed
low-density DNA microarray based on allele-specific probes. The
design, fabrication, validation and analysis of the arrays were
performed following the procedure described elsewhere [17]. In
brief, the PCR products were fluorescently labelled and hybridized
to the DNA microarray in an automated platform (Ventana
Medical Systems, Inc., Tucson, AZ, USA). The microarrays were
scanned (Innopsys S.A., Carbonne, France) and we determined
variants using a developed software that converts the intensity of
the spots into the genotype of each variant.
Statistical analysis
We tested Hardy-Weinberg equilibrium using a x
2 test. All
statistical analyses were performed using the PASW (v. 18.0 for
WINDOWS, Chicago). Genotype/allele frequencies were com-
pared among the four study groups (centenarians, controls,
endurance and power athletes) using a x
2 test with a set at 0.05.
We used logistic regression analysis to analyse the association
between alleles and longevity after adjusting for sex.
ACTN3 and Survival
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There were no failures in sample collection, DNA acquisition or
genotyping procedures, except for 5 centenarians, for which the
amount of DNA gathered from saliva was insufficient to allow
ACTN3 R577X genotype assessment. Parallel genotyping results
showed 100% concordance between the two laboratories.
Genotype distributions met Hardy-Weinberg equilibrium in all
study groups (all P.0.1). Figures 1 and 2 show the genotype and
allele frequencies respectively in the different study groups. The
ACTN3 R577X genotype distributions in our healthy controls
were overall similar to those previously reported in healthy
Spanish adults [10] and European Caucasians, i.e. ,18%
frequency of the XX genotype [7]. There were no differences
in genotype or allele frequencies between centenarians, and
controls or endurance athletes (all P.0.1). We repeated the
analyses by comparing X carriers vs. non-X carriers, or R
carriers and non-R carriers and found no significant differences
between groups (all P.0.1). However, we observed significant
differences in genotype and allele frequencies between centenar-
ians and power athletes: the frequency of X carriers was higher in
the centenarians compared with the power athletes group
(Figure 1, P=0.011), and the frequency of the X allele was also
higher in centenarians than in power athletes (Figure 2,
P=0.019).
The odds ratio (OR) of being a centenarian if the subject had
the X allele was not significant: 1.236 (95% confidence interval
(CI): 0.484–1.803), 1.041 (95% CI: 0.486–2.230), and 1.678 (95%
CI: 0.928–3.033) compared to the control, endurance athletes, and
power athletes group, respectively, after adjusting for sex.
Likewise, the OR of being a centenarian if the subject had the
XX genotype did not reach statistical significance: 1.032 (95%
confidence interval (CI): 0.863–1.234), 1.132 (95% CI: 0.784–
1.636), and 1.165 (95% CI: 0.945–1.437) compared to the control,
endurance athletes, and power athletes group, respectively, after
adjusting for sex.
Discussion
Although the allelic/genotypic frequency of the ACTN3 R577X
polymorphism did not significantly differ between centenarians
and the control population, a major finding of our study was that
overall, the allelic/genotypic distribution of the ACTN3 R577X
polymorphism in centenarians was closest to that of those humans
who arguably show the most ‘extreme’ muscle endurance
phenotypes, i.e. professional road cyclists able to excel in such
demanding events as the Tour de France [10]. Notably, the
frequency of the null XX genotype in our cohort of centenarians
(24%) was the highest ever reported in non-athletic Caucasian
populations, and is only surpassed by the values of the professional
road cyclists we studied (26%) and the elite endurance athlete’s
cohort (made up of various types of Olympic-class endurance
athletes, included road cyclists) of a previous report by Yang et al
on Australian athletes (30%) [9].
Though natural selection in the human genome accelerated
during the past 40,000 years, probably less than 1% of our genes
arose during the late Pleistocene and Holocene epochs (126,000–
8,000 years before present), that is, after the Paleolithic era [4].
Genetically, therefore, we are still citizens of the Paleolithic era
living in the 21st century; our genetic makeup is shaped to support
the balance between energy intake and energy expenditure that
was common to Paleolithic hunter–gatherer societies [3]. Among
these people, survival depended upon the obligatory link between
energy intake (food consumption) and energy expenditure for
ensuring food acquisition [18]. Thus, ‘long time tracking
persistence’ (i.e. mostly endurance or ‘aerobic’ exercise, such as
walking/running 20 or more km/day) was likely necessary for
successful hunting and thus for survival [5,6]. In this context,
genetic variants with a documented influence on exercise/muscle
related phenotypes could also be associated with survival. For
instance, the D allele of the 287 bp Ins(I)/Del(D) polymorphism
[rs1799752] in intron 16 of the angiotensin converting enzyme
(ACE) gene, which has been associated with several exercise
Figure 1. Genotype distribution of the ACTN3 R577X polymorphism in our study cohorts. Symbol: *P=0.011 for centenarians vs. power
athletes.
doi:10.1371/journal.pone.0017558.g001
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people aged 60 years and over [19], seems to be more frequent in
some cohorts of European centenarians compared with their
younger ethnically-matched referents [20,21,22]. Here, we
hypothesized that the ACTN3 R577X variation is a strong
candidate to influence survival over human evolution. Indeed,
among the numerous genes that contribute to the ‘fitness’ or
‘performance’ phenotype, the ACTN3 is the first structural skeletal
muscle gene for which such an association has been demonstrated
[23]. The propagation of ACTN3 deficiency in humans with
marked variations in X-allele frequencies among different ethnic
groups [7,24] has raised the possibility that the X allele has been
positively selected in some populations. Owing to its effect on
skeletal muscle metabolism (see below), the X allele probably
provided some sort of fitness advantage to modern humans
adapting to the novel Eurasian environment [25].
Compared with wild-type mice, the muscles of the a-actinin-3
deficient mouse exhibit 33% higher endurance (during treadmill
running) and a shift towards more oxidative pathways of
metabolism, i.e. increased activity of mitochondrial oxidative
metabolism [11,25]. The XX genotype shows especially high
frequency (26%) in professional road cyclists, who exhibit
extremely high values of aerobic capacity and muscle efficiency.
The high muscle efficiency of these athletes is attributable to a
higher contribution of slow (type I) muscle type fibers compared
with the less efficient type II (‘anaerobic’) subtype, in which a-
actinin-3 is almost exclusively expressed [26]. In addition, a shift
towards more oxidative muscle phenotypes associated with the
XX genotype could have a beneficial influence on health related
phenotypes. Classic studies in rats by Koch and Britton’s group
showed that improved oxidative pathways in mitochondria may be
a common factor linking physical fitness and decreased disease risk
[12,13]. In humans, the metabolic effects of ACTN3 genotype may
act as a modifier of disease severity: the X allele has recently been
shown to benefit exercise capacity phenotypes (i.e. aerobic
capacity) in women with muscle (McArdle) disease [27]. On the
other hand, there appears to be an evolutionary predetermined
‘trade-off’achieved over human evolution through the mainte-
nance of genetic variation by balancing natural selection in
performance traits for power vs. more endurance oriented exercise
tasks [28,29]. That is, an individual is inherently predisposed
towards being more of a ‘sprinter’or a ‘stayer’ [23]. With regards
to this, those genotypes associated with the latter type of
phenotype (e.g. the XX genotype) might have provided a certain
survival benefit over human evolution as opposed to other animals
for which the ability to produce ‘explosive’ muscle actions (rapid
accelerations and decelerations) is vital for survival, i.e. predator
and prey quadrupeds [30].
Published data on ACTN3 genotypes and muscle phenotypes
with regards to ageing are controversial. Compared with the age-
matched wild type mouse, the ageing KO mouse shows greater
loss of fast muscle force generation and male muscle mass, good
maintenance of grip strength, and increased oxidative metabolism
and greater force recovery after fatigue [31]. San Juan et al. [32]
observed no association between ACTN3 genotypes and functional
capacity and muscle phenotypes (included 1RM leg press) in
women aged 61–80 years; whereas others found that (i) in adults
with a mean age ,65 years, the XX genotype was associated with
higher knee extensor concentric peak power compared with RR/
RX genotypes, especially in women [33], and (ii) in women (aged
,60 years on average) the XX genotype was associated with lower
peak torque in knee extensor muscles [34]. Recently, we observed
no major influence of ACTN3 genotypes on muscle phenotypes (leg
and grip strength, walking and stair climbing ability) in
nonagenarians [35]. Differences in the age, baseline physical
capacity and ethnic origin make comparison between studies
difficult. Assessing the putative effects of ACTN3 genotypes on the
muscle phenotypes of centenarians is nevertheless a very difficult
task: the expected poor physical condition and lack of indepen-
dence in most of them (which at least was the case in our cohort)
precludes the use of valid tools for phenotype assessment in this
population.
Figure 2. Allele distribution of the ACTN3 R577X polymorphism in our study cohorts. Symbol: *P=0.019 for centenarians vs. power
athletes.
doi:10.1371/journal.pone.0017558.g002
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group of cases, i.e. being all centenarians. Indeed, a well accepted
approach for identifying those genetic factors that are associated
with ‘longevity assurance’ is to study the genotype of centenarians.
These people are the survival tail of population, and living 100 or
more years is a rare phenotype, i.e. #1 every 10,000 people [1,2].
However, our results should be taken with caution due to the
relatively low number of centenarians we studied. Indeed, a
sample size of ,400 centenarians would have been needed in
order to reach sufficient statistical power ($0.8). To note is that we
only included males in the two athletic cohorts due to the higher
competition success (at the international level) of Spanish male
athletes compared to their women counterparts. This ensured that
both cohorts were really in both end-points of the human
performance continuum. With regards to this, it must be kept in
mind that the X allele seems to be more influential to elite athletic
status in women than in men [9]. It thus remains to be determined
if our results can be corroborated with women’s athletic cohorts.
Future studies are also necessary with larger samples of
centenarian males in order to replicate the findings we obtained
with our cohort of centenarians, which was mainly composed of
women. On the other hand, longevity is likely a complex,
polygenic trait, which could be influenced by numerous gene-
environment and gene-gene interactions, including those interac-
tions between genetic variants that might not influence longevity
individually.
In summary, although we did not find significant differences
with the younger, control population, overall the ACTN3 genotype
profile of centenarians resembles that of world-class elite
endurance athletes and seems to differ from that of elite power
athletes. Our preliminary data would suggest a certain ‘survival’
advantage brought about by a-actinin-3 deficiency and the
‘endurance’/oxidative muscle phenotype that is commonly
associated with this condition; yet, more data on larger cohorts
and on other ethnicities are necessary. Despite its uniqueness, the
‘oldest old’ is the most rapidly growing age group in western
countries [36]. It is also the least physically active, and that
generating the highest healthcare expenditures, largely due to loss
of physical function [37]. Thus, identifying those genetic variants
that are associated with exceptional longevity and rate of decline of
physical function at the end of the human lifespan is of potential
medical relevance. Our results might provide insights into the
putative role on human survival of some genetic polymorphisms
which are known to influence muscle function, of which the
ACTN3 R577X is currently the best example.
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